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The syntheses, the biological evaluation, and the structure-activity relationships of a novel series 
of l,8-dihydroxy-9(10H)-anthracenones bearing acyl-, alkyl- , or alkylidene-linked aromatic 
substituents in the 10-position are described. The phenylacyl and phenylalkylidene analogs were 
far more potent inhibitors of 5-lipoxygenase (5-LO) from bovine polymorphonuclear leukocytes 
(IC50 values in the 10 - 7 M range) than the antipsoriatic drug anthralin, whereas phenylalkyl analogs 
were only weak inhibitors. Among the active compounds were both potent generators of hydroxyl 
radicals, as determined by deoxyribose degradation, and strong reducers of the stable free radical 
2,2-diphenyl-l-picrylhydrazyl ( D P P H ) . However, several derivatives of this series maintained 
5-LO inhibitory activity but d id not generate hydroxyl radicals and were not reactive with D P P H . 
In particular, phenylacyl analogs were also 6 times more efficient in inhibition of l ipid peroxidation 
in model membranes than anthralin. Structure-activity relationships have shown that the presence 
of free phenolic groups in the attached aromatic ring is beneficial but not required for 5-LO 
inhibitory potency. The inhibitory potency in the 10-phenylacyl series increased with the length 
of the acyl chain with three methylene units being the optimum, suggesting a specific enzyme 
interaction which would not be expected for nonspecific redox inhibitors. 
Psoriasis is a widespread, chronic inflammatory and 
scaling skin disease, mainly characterized by increased 
cell proliferation of the epidermis.1 There is evidence, 
however, that hyperproliferation alone is not sufficient to 
produce a psoriatic lesion, and it has been suggested that 
the inflammatory component is an important part of the 
disease process.2 The etiology is as yet unknown, but 
psoriasis is known to be associated with numerous bio-
chemical abnormalities.2 A characteristic of lesional skin 
is the elevated level of oxygenation products of arachidonic 
acid. In particular, evidence has been provided showing 
the enhanced production of 5-lipoxygenase (5-LO) prod-
ucts such as leukotriene B 4 ( L T B 4 ) and 5-hydroxyeico-
satetraenoic acid (5-HETE) in psoriasis.3-* Moreover, the 
effects of 5-LO products in the skin correlate with several 
pathological features of psoriasis, in particular,.leukocyte 
migration and enhanced cell proliferation.7 Thus, regu-
lation of 5-LO pathways has become an important target 
for therapeutic intervention. 8- 1 0 
Probably the most commonly used topical agent for the 
treatment of psoriasis is anthralin (l,8-dihydroxy-9(10if)-
anthracenone, dithranol, 1), which is free of mutagenic 
property and even exhibits some antimutagenic activity. 1 1 
However, anthralin therapy causes unpleasant side effects. 
For example, nonaffected skin surrounding a psoriatic 
lesion to which anthralin is applied is frequently irritated 
and stained. 1 2 Thus, patient compliance is reduced. The 
mechanism of the irritancy and the mode of action of 
anthralin are still not fully understood, but substantial 
evidence suggests that free radicals and active oxygen 
species are involved. 1 3" 1 9 Although these species may be 
responsible for the skin irritation and the production of 
staining products, they are presumably central to the 
clinical efficacy of the drug. Hence it seems difficult to 
separate main and side effects. Anthralin may act both 
as an antioxidant and as a prooxidant. 2 0 In addition, it 
was shown to inhibit the 5- and 12-LO pathways of 
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arachidonic acid metabolism in vitro. 2 1* 2 2 The biosynthesis 
of eicosanoids occurs via the formation of free radicals. 2 3 
Therefore, compounds with antioxidant properties would 
be expected to be potential inhibitors of 5 - L O . 2 4 - 2 8 
Furthermore, oxygen free radicals, which are inflammatory 
mediators of considerable importance, may be inactivated 
by such Compounds. 2 9» 3 0 
Although there have been attempts to develop new 
therapeutically effective derivatives of anthralin, such as 
triacetoxyanthracene3 1 2 and butantrone 1 2 (3) for which 
initial reports were promising, later reports have indicated 
that these compounds were less effective and more 
irritating than anthralin itself.32*33 Accordingly, there is 
still need for improved antipsoriatic anthrones that are 
effective at low dose with low irritancy. 
The aim of the present study was to modulate the 
intensity of active oxygen release by l,8-dihydroxy-9(10Ä)-
anthracenones, which may permit a separation of anti-
psoriatic and inflammatory effects. This modulation can 
be achieved by partially blocking the C-10 position, which 
is responsible for the production of the superoxide radical, 1 4 
a precursor in the formation of the hydroxyl radical by 
anthralin. 1 5 
A series of anthralin analogs bearing acyl-, alkyl-, or 
alkylidene-linked aromatic substituents in the 10-position 
was synthesized to investigate the effects on hydroxyl-
radical formation and 5-LO inhibition. Structure-activity 
relationships are discussed with respect to the following 
redox properties of the compounds which were recently 
established for anthralin: 1 9 reactivity against the stable 
free radical 2,2-diphenyl-l-picrylhydrazyl (DPPH), proox-
idant potential as determined by deoxyribose degradation, 
and inhibitory effect on lipid peroxidation in model 
membranes. 
Chemistry 
Introduction of the 10-acyl functionality onto the 
anthrone nucleus (compounds 4a-u) was achieved by 
reaction of the appropriate acyl chlorides with anthralin 
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Chart I. Anthralin (1), Resonance-Stabilized 
Deprotonated Forms of Anthralin l a , 
Triacetoxyanthracene 2, Butantrone (3), and Lonapalene 
OH O OH 
OAc 
lonapalene 
Scheme I ' 
OH O OH 
R 
4a-4q 
4d-4f,4l R.OCHaPh 
)(b) 
4r-4u R«OH *S 
°R and X are defined in Table L Reagents: (a) anthralin, pyridine, 
toluene, 80 °C, N 2 ; (b) Pd-C, H 2 , THF, room temperature, atmo-
spheric pressure. 
under weakly basic conditions, where acylation takes place 
at the C-10 position via the carbanion (Scheme I). 3 4 The 
required acyl chlorides were prepared from the corre-
sponding acids according to literature methods.35*36 Be-
cause ether cleavage of 4c with boron tribromide resulted 
in loss of the acyl function at C-10, the desired phenolic 
analogs 4 r - u were prepared by hydrogenolytic cleavage 
of benzyl ethers 4d-f and 41 (Scheme I). 
Scheme II illustrates the synthesis of the 10-phenyl-
alkylidene derivatives 7a-r. To this end, a new method 
for attaching carbon substituents to the 10-position of 
anthralin had to be established. Attempts to obtain the 
desired compounds by condensation of anthralin with 
various benzaldehydes in the presence of piperidine or 
other basic additives failed. However, the use of a-chloro 
methyl ethers proved to be successful. Thus, conversion 
of suitable aldehydes to their dimethyl acetals followed 
by treatment with acetyl chloride provided the corre-
Scheme I I ' 
OY ^ CÄ -* 
R R 
5a - 5m 
OH O OH OH O OH 
7f-7h R - O C H 3 
7p-7r R = OH 
71 8 
°R and n are defined in Table I. Reagents: (a) trimethyl 
orthoformate, MeOH, concentrated H2SO4, acetyl chloride, thionyl 
chloride, 50-60°C; (b) anthralin, DBU, CH2CI2, N 2,0 °C; (c) pyridine, 
N2,116 °C; (d) DBU, MeOH, room temperature, 3 min; (e) DBU, 
MeOH, room temperature, 10 h; (f) H2SO4 50%, glacial acetic acid; 
(g) MeOH, concentrated H2SO4; (h) BBr 3, CH2CI2, -70 °C, N 2 . 
sponding a-chloro methyl ethers 5a-m. In most cases, 
a-chloro methyl ethers were used in crude form because 
purification led to decomposition. Alkylation of anthralin 
with a-chloro methyl ethers in the presence of the non-
nucleophilic base 13-diaz^icyclo[5.4.0]undec-7-ene (DBU) 
at 0 °C gave l,c^dmydroxy-10-(l-methoxy-ü>-phenylalkyl)-
9(10if)-anthracenones 6a-m. Base-catalyzed (pyridine) 
elimination of a molecule of methanol afforded 7a-h and 
7j-m in good yields. Derivative 7o was obtained by acid 
hydrolysis of benzonitrile 7e and subsequent esterification 
of the acid 7n. The 10-(hydroxyphenyl)methylene de-
rivatives 7p-r were obtained by deprotection of the 
corresponding methyl ethers 7f-h with boron tribromide 
in methylene chloride. Under identical conditions as 
described for 7a-h, conversion of 6i (n = 1) afforded an 
isomeric mixture of 7i and 8 in a 65:35 ratio. 7i was 
prepared selectively from 6i by reaction with D B U at room 
temperature (3 min). Further reaction (10 h) of 7i with 
D B U provided the isomerically pure (>99%) 8 as con-
firmed by H P L C analysis. Coupling constants of the 
olefinic protons (J = 15 Hz) indicated the compound was 
in the E configuration. 
The C-10-benzylated anthralin derivatives (9a-c and 
10) were prepared as outlined in Schemeln. The synthesis 
of the monobenzylated compounds 9a-c was accomplished 
by reaction of anthralin with the corresponding benzyl 
halides in the presence of potassium carbonate in acetone. 
Table I. Redox Properties of and 5-LO Inhibition in Bovine PMNL by 10-Phenylacyl- and 10-Phenylalkyhdene-Substituted 
l,8-Dihydroxy-9(10H)-anthracenones 
OH O OH OH O OH 
compd Xor n 5-LO ICw (MM)« ÄDPPH ( M - 1 sr1)* 
deoxyribose degradation 
Oxmol of MDA/mmol)e LPOIC M (MM)* 
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4b 
4c 
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4e 
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4h 
4i 
4j 
4k 
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4m 
4n 
4o 
4p 
4q 
4r 
4s 
4t 
4u 
7a 
7b 
7c 
7d 
7e 
7f 
7g 
7h 
7i 
7j 
7k 
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7m 
7n 
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7p 
7q 
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CH 2 
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(CH2)2 
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C H 2 
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0 
0 
0 
0 
0 
0 
0 
0 
1 
2 
2 
3 
4 
0 
0 
0 
0 
0 
H 
4 - N 0 2 
4-OCH3 
4-OCHzPh 
3.4- (OCH2Ph)2 
3,4,5-(OCH2Ph)3 
3.5- (t-Bu)R4-OH 
H 
4-OCH3 
3,4-(OCH3)2 
3,4,5-(OCHa)3 
4-OCH2Ph 
H 
4 - N 0 2 
3- OCH3 
H 
H 
4- OH 
3,4-(OH)2 
3,4,5-(OH)3 
4-OH 
H 
4-CH3 
4-CF3 
4 - N 0 2 
4-CN 
4-OCH3 
3,4-(OCHs)2 
3,4,5-(OCH3)2 
H 
H 
4-OCH3 
H 
H 
4-COOH 
4-CO2CH3 
4-OH 
3,4-(OH)2 
3,4,5-(OH)3 
11 
7 
0.5 
0.6 
(34% at 30) 
(0% at 30) 
10 
0.5 
1 
17 
14 
2 
17 
6 
3 
0.3 
2 
14 
11 
0.3 
1 
(34% at 30) 
(23% at 30) 
(33% at 30) 
2 
(34% at 30) 
«10% at 30) 
«10% at 30) 
«10% at 30) 
(35% at 30) 
6 
(24% at 30) 
(21% at 30) 
(0% at 30) 
«10% at 30) 
«10% at 30) 
4 
0.5 
0.4 
16.4 ± 1.7 
63.7 ± 6.6 
15.1 ± 0.7 
13.3 ± 0.6 
15.0 ± 0.4 
15.3 ± 0.3 
»100* 
10.3 ± 1.4 
7.4 ± 0.7 
8.7 ± 0.8 
10.3 ± 1.1 
8.8 ±0.1 
>100* 
»100* 
>100* 
10.1 ± 0.2 
10.8 ± 0.9 
14.7 ± 1.3 
»100* 
»100* 
7.8 ± 0.5 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
c 
>100* 
»100* 
»100* 
<0.2 
<0.2 
<0.2 
<0.2 
<0.2 
<0.2 
<0.2 
<0.2 
1.40 ± 0.17/ 
<0.2 
<0.2 
<0.2 
1.66: 
0.88: 
i 
<0.2 
<0.2 
0.36: 
6.26: 
2.99: 
2.59: 
>±0.04/ 
\ ± 0.18/ 
; ± 0.07/ 
;±0.28^ 
) ± Q.2& 
I ± 0.21/ 
<0.15 
<0.15 
<0.15 
<0.15 
<0.15 
<0.15 
<0.15 
<0.15 
<0.15 
<0.15 
<0.15 
<0.15 
<0.15 
<0.15 
<0.15 
<0.15 
0.44 ± 0.01/ 
6.03 ± 0.08/ 
2h 
2^  
2* 
2* 
2» 
1 
2* 
8* 
i 
i 
14 
4* 
2* 
8* 
2* 
2* 
8 Inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL. Inhibition was significantly different with respect to that of the control, 
n = 3 or more, P < 0.01. Values in parentheses are percent inhibition at the indicated concentrations Q*M), and standard errors average 10% 
of the indicated values. 6 Reducing activity against 2,2-diphenyl-l-picrylhydrazyl with an equimolar amount of the test compound.c Not 
reactive; &DPPH < 1 M _ 1 s-1- d Highly reactive (approximate values).9 Deoxyribose-damaging property as a measure of hydroxy 1-radical formation. 
Indicated values are pinol of malondialdehyde/mmol of deoxyribose released by 75 pM. test compound (controls <0.1). / Values are significantly 
different with respect to the control, P < 0.01.' Inhibition of lipid peroxidation in bovine brain phospholipid liposomes; n = 3 or more. h Values 
are significantly different with respect to anthralin, P < 0.01.1 Not determined. 
The dibenzylated 10 was obtained in an analogous manner 
using the requisite molar ratio of benzyl chloride. 
Biological Evaluation 
Inhibition of 5-Lipoxygenase. The an throne deriv-
atives were evaluated for their ability to inhibit the 
production of L T B 4 and 5 -HETE in isolated bovine 
polymorphonuclear leukocytes ( P M N L ) . 3 7 ' 3 8 Leukotriene 
biosynthesis was initiated with Ca ionophore A23187. L T B 4 
and 5 - H E T E concentrations were measured by reversed-
phaseHPLC with U V detection. Table I summarizes the 
inhibitory potencies of the new compounds as expressed 
by their IC50 values. Several compounds in our series had 
IC50 values ranging between 0.3 and 0.6 uM and were far 
more potent than anthralin (37 uMin this test). Data for 
known antipsoriatic anthrones, the standard 5-LO inhib-
itor nordihydroguaiaretic acid (NDGA) and lonapalene,9 
a 5-LO inhibitor that showed clinical efficacy as an 
antipsoriatic agent, are given in Table II. The effect of 
anthralin itself on arachidonic acid lipoxygenation was 
previously reported. In human neutrophils and bovine 
neutrophils, it inhibits the production of L T B 4 with IC50 
Table II. Redox Properties of and 5-LO Inhibition in Bovine PMNL by Anthralin Derivatives and Standard Drugs 
5-LO IC50 (MM)° fepppH ( M - 1 s-1)6 deoxyribose degradation 0*mol of MDA/mmol)e LPOIC50 (jiM)* 
NDGA 0.4 »100* 
lonapalene 0.5 c 
anthralin 37 24.2 ± 4.2 
butantrone 33 7.0 ± 0.6 
triacetoxyanthracene (15% at 30) c 
See footnotes of Table I. 
Scheme III* 
OH O OH OH O OH 
9a - 9c 10 
flX = CI or Br. R = H, N0 2 , or OCH 3. Reagents: (a) K 2 C0 3 , KI, 
acetone. 
values of 7-74 pM (depending on cell density) and 37 /*M, 
respectively.22*39 N D G A and lonapalene gave IC50 values 
of 0.4 and 0.5 M M , respectively, in this test. 1,8,9-
Triacetoxyanthracene and butantrone, which had been in 
clinical trials for the treatment of psoriasis, are only 
moderate inhibitors. 
Structure-activity studies showed that in general the 
10-phenylacyl-substituted analogs 4a-u were more effec-
tive than the C-10 phenylalkylidene derivatives 7a-r. The 
10-phenylalkyl- or 10,10-bis(phenylalkyl)-substituted com-
pounds 6a-m, 8, 9a-c, and 10 were without appreciable 
effect (data not shown). 
The 10-phenylacyl-substituted derivatives showed con-
sistently high activity. Introduction of ether groups in 
the 4-position of the aromatic ring (4c and 4d) strongly 
increased activity as compared to 4a, although the di- and 
tribenzylated compounds 4e and 4f were notably less active 
or inactive, respectively, probably on account of high 
lipophilicity and limited solubility in the test system. The 
presence of free phenolic groups did not necessarily lead 
to improved efficacy in inhibiting 5-LO as compared to 
nonphenolic compounds. Only if the terminal aromatic 
ring was substituted by three phenolic groups (4t) was 
inhibitory action significantly improved as compared to 
that of the unsubstituted derivative 4a. Furthermore, the 
inhibitory effects increased with the length of the acyl 
chain linking the anthrone nucleus and the phenyl ring 
terminus. Compounds 4a, 4h, 4p, and 4q demonstrate 
the beneficial effect of inserting methylene groups between 
the C-10 carbonyl group and the phenyl rest. Optimal 
activity was observed when the length of the chain was 
three carbons (4p). A derivative with a trans double bond 
in the linking chain (4m) was markedly less active than 
the corresponding saturated chain compound (4h). Com-
parison of the IC50 value obtained for butantrone (3) with 
those obtained for the w-phenyl derivatives 4h and 4p, 
where the 10-butyryl substituent is replaced by a phen-
ylpropionyl or phenylbutyryl group, respectively, clearly 
demonstrates that a terminal aromatic ring is required. 
The mere presence of an acyl substituent at C-10 of 
anthralin does not necessarily lead to enhanced 5-LO 
inhibitory activity. 
In the 10-phenylalkylidene series, with the exception of 
the 4-nitro derivative 7d and the compound 7j, compounds 
0.23 ± 0.01/ lh 
<0.15 >50 
2.89 ± 0.14/ 12 
0.24 ± O.OSf 4h 
<0.15 i 
which lack free hydroxy groups in the attached phenyl 
ring were only moderate inhibitors, whereas the phenolic 
analogs 7p-r strongly inhibited L T B 4 formation. The 
effect of chain length on activity was less pronounced in 
the phenylalkylidene series; however, the phenylpropy-
lidene chain was optimal for compounds terminated with 
an unsubstituted phenyl rest (7j). 
Finally, substitution of one or both protons at C-10 of 
anthralin by benzyl groups (9a-c and 10) abolished 5-LO 
inhibition, in accordance with the findings that 10-mono-
and dialkylation of anthralin results in loss of antipsoriatic 
activity. 4 0 ' 4 1 
To rule out apparent inhibition due to nonspecific toxic 
effects of the potent derivatives, the treated P M N L were 
checked for viability using the trypan blue exclusion test. 
Cell viability was always greater than 80%. 
Since the use of intact cells requires penetration of the 
test compound into the cell, control experiments were 
performed using an homogenate of bovine P M N L which 
was obtained by sonification of the cell suspension.4 2 The 
two highly effective compounds 4p and 4t and the less 
effective compounds 4f and 7b were tested at both 3 and 
30 M M . However, L T B 4 synthesis was inhibited with 
comparable potency whether it was determined in whole 
cells or under cell-free conditions. Thus, there is no barrier 
to penetration of the compounds. In addition, this 
demonstrates that the compounds act directly on 5-LO. 
Effects on other targets, e.g., 5-LO-activating protein, 4 3 
can be excluded. 
Lipophilicity. In some studies on 5-LO inhibitors, 
relationships between the log of the octanol/ water partition 
coefficients (log P) and the structural changes resulting 
in increased activity were reported. 2 5 ' 2 6 ' 4 4 Thus, as a 
measure of lipophilicity, we determined the log P values 
of the new compounds by a standard H P L C procedure.4 5 
In our case, there was no clear relationship found between 
5-LO inhibition and lipophilicity. The compounds ex-
hibited a wide range of log P values (2.61-5.67, Table III). 
In general, changes in lipophilicity were well tolerated. 
Compound 4t as the most hydrophilic representative as 
well as the lipophilic 4d exhibited high activity. The most 
lipophilic representative with acceptable activity was 7j, 
although solubility limited the assay concentrations of 
compounds with greater lipophilicity. 
Antioxidant Determination. Because conversion of 
arachidonic acid into L T B 4 by 5-LO is a radical-based 
oxidation, it is not surprising that most 5-LO inhibitors 
possess redox properties and can be considered as anti-
oxidants/free-radical scavengers.23 These compounds 
inhibit 5-LO by donating an electron during enzyme 
catalysis. Because a radical-scavenging antioxidant reacts 
rapidly with the stable free radical D P P H , 4 6 ' 4 7 we deter-
mined the reactivities of the new compounds with D P P H 
by the decrease in absorbance at 516 nm (Table I). 
Phenylacyl substitution at C-10 of anthralin substantially 
reduced reactivity with D P P H as compared to that of 
anthralin (Table II), whereas substitution of both C-10 
hydrogen atoms of anthralin by phenylalkylidene groups 
nearly abolished reactivity with D P P H . On the other 
hand, substitution on the phenyl moiety of the side chain 
by two or three hydroxy groups (4s, 4t, 7q, and 7r) 
dramatically increased redox activity, reflecting the re-
ducing capability of the phenolic hydroxyl. Similar 
reducing effects were observed for the cinnamoyl deriv-
atives 4m-o and the 2,6-di-tert-butylphenol derivative 4g. 
The reactivity of compound 7p which has only one phenolic 
group is explained by increased resonance stabilization of 
the corresponding radical. 
Hydroxyl-Radical Production. Further studies on 
the redox behavior of the new compounds have been 
performed using the deoxyribose assay, which is a sensitive 
test for the production of hydroxyl radicals. 4 8 The release 
of thiobarbituric-acid-reactive material (expressed as 
malondialdehyde, M D A ) is a measure for hydroxyl-radical 
formation and thus reflects prooxidant properties of the 
compounds. 4 9 ' 5 0 The data obtained from this test (Table 
I) demonstrate that with the exception of the C-10 
cinnamoyl anthralin derivatives (4m-o) and the com-
pounds with free phenolic groups in the C-10 substituent 
(4s-u, 7q, and 7r), the formation of hydroxyl radicals was 
substantially reduced with respect to anthralin (Table II). 
The phenylalkyl substituted compounds 8, 9a-c, and 10 
did not produce hydroxyl radicals (data not shown). The 
catechol 4s and the pyrogallol derivative 7r led to the 
release of even larger amounts of M D A than did anthralin 
(Table II), indicating enhanced formation of hydroxyl 
radicals. Furthermore, there is no direct relationship 
between 5-LO inhibitory potency and formation of hy-
droxyl radicals by l,8-dmydroxy-9(10if)-anthracenones. 
Inhibition of Lipid Peroxidation. The inhibitory 
effect on lipid peroxidation of some representative com-
pounds was evaluated with bovine brain phospholipid 
liposomes which provide an ideal model system for lipid 
peroxidation studies.5 1 L ip id peroxidation was stimulated 
with Fe 3 +/ascorbic acid. 5 2 The 10-phenylacylated com-
pounds tested gave IC50 values of 1-2 uM (Table I), being 
significantly more efficient than anthralin (12MM). 1 9 T1IUS, 
variation of the phenylacyl substituent while leading to 
significant changes in 5-LO inhibitory activity can main-
tain high activity in inhibition of l ipid peroxidation. 
Surprisingly, even compounds that were not reactive with 
D P P H and did not generate hydroxyl radicals did show 
activity in this test (e.g., 4a and 7j). For comparison, the 
compounds 6a and 10 were without appreciable effect (IC50 
> 50, data not shown). 
Discussion 
Our results show that the l,8-dihydroxy-9(10H)-an-
thracenone nucleus, although not a potent inhibitor of 
5-LO in itself, can provide a useful template for the design 
of potent inhibitors of leukotriene biosynthesis. Moreover, 
the results support our hypothesis that structural mod-
ification of anthralin may lead to control of the release of 
active oxygen species, as determined by the potency of 
the compounds to generate hydroxyl radicals. Although 
5-LO inhibitory action of l,8-dihydroxy-9(10if)-anthra-
cenones was not proportionally related to the generation 
of hydroxyl radicals, compounds which were potent 
generators of hydroxyl radicals were also effective in 5-LO 
inhibition (4i, 4s-u, and 7r). Furthermore, those com-
pounds that were substituted by phenylalkyl groups (8, 
9a-c, and 10) at C-10, which resulted in the loss of 
hydroxyl-radical formation, were inactive. On the other 
hand, decreasing or abolishing the potency of hydroxyl-
radical formation by incorporation of a 10-phenylacyl or 
10-phenylalkylidene substituent did not necessarily reduce 
5-LO inhibition. 
Many 5-LO inhibitors inhibit lipid peroxidation, 5 3 ' 5 4 and 
it is believed that 5-LO inhibition by those substances is 
due to scavenging of intermediate radicals that are formed 
within the active site of the enzyme. The most potent 
5-LO inhibitors of our series were all effective inhibitors 
of l ipid peroxidation in model membranes. However, 
examination of the reactivities of the compounds against 
D P P H in Table I shows the lack of correlation between 
the ability to intercept a free radical and 5-LO inhibitory 
potency, suggesting that a simple antioxidant effect does 
not explain the activity of several inhibitors. The inhib-
itory effects of these compounds appear to be due to 
specific enzyme interaction rather than nonspecific redox 
properties. 
The anthralin anion (la) is the key intermediate in the 
oxidation process, which involves a one-electron transfer 
from the anion to oxygen to give the anthralin- 10-yl free 
radical and the active oxygen species.14 5-LO contains a 
non-heme iron that is converted to the ferric form upon 
activation. 5 5 Thus, it may be expected that similar to the 
oxidation process, electron transfer from the anthralin 
anion to the active ferric form of 5-LO results in an 
inactivated enzyme (ferrous form), according to a proposed 
mechanism. 5 6 The so-called redox-active inhibitors are 
supposed to exert their action by this mechanism.5 7 In 
addition to the redox properties, other factors such as an 
appropriate geometry of the molecules when bound to the 
active site of the enzyme may be responsible for the 5-LO 
inhibitory activities of the novel anthralin analogs. This 
is supported by the fact that for these compounds, a 
definite length of the chain linking the anthrone nucleus 
and the phenyl rest was optimal for activity. 
It has been suggested that the generation of active 
oxygen species by anthralin is responsible for the inflam-
mation of uninvolved skin. 1 7 Hence, inhibitors which lack 
hydroxyl-radical formation may be expected to be devoid 
of skin-irritating properties. Furthermore, redox inhib-
itors are oxidized during their action on L O . 5 8 Conse-
quently, their stability is limited. 5 9 Indeed, H P L C analysis 
of the incubation mixtures at the end of the 5-LO assay 
revealed that anthralin was almost completely degraded 
to its dimer bianthrone and the corresponding an-
thraquinone, danthron. Both metabolites are not effective 
in 5-LO inhibit ion. 2 2 ' 3 9 Contrary to anthralin, compounds 
4p and 7j of our series were not appreciably degraded 
during the 5-LO assay, and they were not hydrolyzed to 
anthralin. 
In conclusion, we have presented l,8-dihydroxy-9(10H)-
anthracenone derivatives (see Tables III and IV for 
chemical data) which show potent inhibition of 5-LO in 
bovine P M N L . Several compounds were about a 100-fold 
more potent than anthralin and butantrone in arachidonic 
acid 5-LO inhibition, among which were more powerful 
generators of hydroxyl radicals than anthralin, while some 
compounds maintained 5-LO inhibitory potency but did 
not generate hydroxyl radicals. Several compounds are 
being evaluated as potential antipsoriatic agents devoid 
of inflammatory and staining effects. 
Table III. Chemical Data of 10-Phenacyl- and 
10-Phenylalkylidene-Substituted 
l,8-Dinydroxy-9(10H)-anthracenones 
log mp yield chromatography 
compd P formula0 (°C) (%) solvent (vol % )c anal.d 
4a 4.24 C22H1604 178-179 36 MC/H (7-3) C,H 
4b 3.96 C22H 1 6 N0 6 20 -^211 15 MC/H (4-1) C, H , N 
4c 4.20 C23H18O6 169-170 45 MC C,H 
4d 5.01 C29H22O5 162-163 40 MC/H (4-1) C,H 
4e 5.43 CaeHaA, 147-149 30 MC/H (7-3) C,H 
4f 6.11 C43H34O7 124-125 15 MC/H (9-1) C,H 
4g 5.33 C30H32O5 184-186 34 MC/H (1-1) C,H 
4h 4.63 C23H1804 126-128 40 MC/H (7-3) C,H 
4i 4.72 C24H20O5 108-120 17 MC C,H 
4j 4.21 C26H22O6 115-118 10 MC C,H 
4k 4.06 C26H24O7 118-120 41 MC C,H 
41 5.63 CsoH^Os 140-142 36 MC/H (3-2) C,H 
4m 4.60 C23Hi604 205-108 30 MC/H (3-2) C,H 
4n 4.23 C23H16NO6 225* 5 MC C, H, N 
4o 4.68 C^HigOe 162-166 36 MC/H (3-2) C,H 
4p 4.74 C24H20O4 146-147 44 MC/H (7-3) C,H 
4q e C28H22O4 128-129 43 MC/H (7-3) C,H 
4r 3.38 C22H16O5 178-179 70 MC/E (3-2) C,H 
4s 3.00 C^HieOe 180* 55 MC/E (4-1) C,H 
4t 2.61 C22H16O7 200* 80 MC/M (19-1) C,H 
4u 3.73 CzjHigOß 190-194 45 MC/EA (4-1) C,H 
7a 5.44 C 2 iH 1 4 0 3 161 90 MC C,H 
7b 5.83 C22H16O3 146-147 80 MC C,H 
7c 5.48 C22H13F303 151 65 P/E (4-1) C,H 
7d 4.96 C21H13NO6 172-175 75 P/EA (7-3) C , H , N 
7e 4.58 C22H13NO3 209 76 MC C, H , N 
7f 5.53 C22H16O4 165 85 MC C,H 
7g 5.05 C23H18O5 158 87 MC C,H 
7h 4.85 C24H20O6 211-212 84 MC C,H 
7i 5.61 C22H16O3 12&-129 55 MC C,H 
7j 5.67 C23H18O3 143-144 52 P/EA (7-3) C,H 
7k 4.38 C24H20O4 134-136 47 MC C,H 
71 e C24H20O3 84-86 65 MC C,H 
7m e C25H22O3 59 54 MC C,H 
7n 4.40 C22H14O6 280 85 C,H 
7o 5.35 C23H16O6 167-168 58 MC C,H 
7p 4.52 C21H14O4 220-221 69 MC/E (9-1) C,H 
7q 3.94 C21H14O5 216 78 MC/E (3-7) C / H 
7r 3.32 C21H14O6 211-212 60 E C , H ' 
ö All new compounds displayed ^ - N M R , FTIR, UV, and MS 
spectra consistent with the assigned structure. 6 Decomposition.' E 
= ether, EA = ethyl acetate, H = hexane, M = methanol, MC = 
methylene chloride, and P = petroleum ether (40-60). d Elemental 
analyses were within ±0.4 % of calculated values except where stated 
otherwise. * Not determined. > C: calcd, 72.83; found, 71.36. ' H : 
calcd, 3.89; found, 4.74. 
Experimental Section 
Melting points were determined with a Büchi 510 melting point 
apparatus and are uncorrected. Chromatography refers to 
column chromatography on silica gel (E. Merck, 70-230 mesh). 
In most cases, the concentrated crude products obtained by 
chromatography using the indicated eluants (Tables IHand IV) 
were treated with a small amount of hexane to induce precip-
itation. *H NMR spectra were recorded with a Varian E M 390 
(90 MHz) or a Bruker Spectrospin W M 250 spectrometer (250 
MHz), using tetramethylsilane as an internal standard. Fourier-
transform IR spectra (KBr) were recorded on a Nicolet 510M 
FTIR spectrometer. Mass spectra (EI, unless otherwise stated) 
were obtained on a Varian MAT CH5 spectrometer (70 eV). HPLC 
(Kontron 420, 735 LC UV detector) was performed on a 250- x 
4-mm column packed with Nucleosil Cis (7-^m particles; Bischoff, 
Leonberg, Germany). 
Preparation of Acyl Chlorides. Acyl chlorides were pre-
pared from the corresponding acids60*61 by following standard 
literature procedures.36*36 In most cases, the crude products were 
used in the subsequent acylation steps. 
General Procedure for the Preparation of 1,8-Dihydroxy-
10-(l-oxo-c^-phenylalkyl)-9(10H)-anthracenones 4a-q. 1,8-
Dihydroxy-10-(l-oxo-4-phenylbutyl)-9(1017)-anthra-
cenone (4p). To a solution of anthralin62 (1,1.13 g, 5 mmol) in 
absolute toluene (80 mL) and dry pyridine (0.55 mL, 7 mmol) 
was added drop wise a solution of phenylbutyryl chloride63 (1.30 
g, 7 mmol) in absolute toluene (10 mL) under N 2 . The reaction 
mixture was heated to 80 °C for 3 h (the reaction mixture was 
stirred at room temperature for compounds 4b, 4d, 4e-g, and 
4m-o), cooled, and filtered, and the filtrate was evaporated. The 
residue was purified by chromatography. Re crystallization from 
toluene/hexane gave yellow needles (Table HI): l H NMR (CDCI3) 
5 12.25 (s, 2H), 7.65-6.85 (m, 11H), 5.25 (s, 1H), 2.40-1.95 (m, 
4H), 1.80-1.55 (m, 2H); FTIR 1713 (CO), 1632 cm 1 (CO-HO); 
MS m/z 372 (2). Anal. (C24H20O4): C, H. 
General Procedure for the Hydrogenolytic Cleavage of 
Benzyl Ethers 4r-u. l^-Dihydroxy-10-[2-(3,4,5-trihydrox-
yphenyl)-l-oxoethyl]-9(10J7)-anthracenone (4t). A solution 
of 4f (0.5 g, 0.75 mmol) in absolute THF (50 mL) was hydrogenated 
over 10% Pd-C (150 mg) at room temperature and atmospheric 
pressure. After the requisite amount of hydrogen had been taken 
up (24 h, TLC control), the catalyst was removed by filtration 
and the solution was evaporated. The product was purified by 
chromatography. Recrystallization from absolute ethanol af-
forded yellow crystals (Table III): *H NMR (DMSO-cfe) 6 11.89 
(s, 2H), 8.77 (s, 3H), 7.61-6.93 (m, 6H), 6.00 (s, 2H), 5.70 (s, 1H), 
3.73 (s, 2H); FTIR 3432 (OH), 1696 (CO), 1634 cm 1 (CO-HO); 
MS m/z 392 (5). Anal. (C^H^O?): C, H. 
Preparation of a-Chloro Methyl Ethers 5a-m. The ap-
propriate aldehydes were converted to the corresponding dimethyl 
acetals and then to the a-chloro methyl ethers according to 
literature procedures.64*65 
General Procedure for the Preparation of 1,8-Dihydroxy-
10-( l-methoxy-a>-phenylalkyl)-9( 10H)-anthracenones 6a-m. 
13-Dihydroxy-10-(l-methoxy-3-phenylpropyl)-9(10H)-an-
thracenone (6j). To a solution of 1 (0.99 g, 4.4 mmol) and DBU 
(0.7 g, 4.6 mmol) in dry CH 2C1 2 (50 mL) was added dropwise at 
0 °C a solution of (3-chloro-3-methoxypropyl)benzene (1.02 g, 
5.5 mmol), which was in turn prepared from (3,3-dimethoxypro-
pyl) benzene,66 in dry CHfih (10 mL), and the solution was allowed 
to stir at 0 °C for 30 min under N 2 . The reaction mixture was 
shaken thoroughly with 2 N HCl, and the organic phase was 
washed with saturated aqueous NaCl, dried over Na2S04, and 
evaporated. The residue was purified by chromatography. 
Recrystallization from absolute ethanol gave yellow crystals 
(Table IV): l H NMR (CDC13) 512.22 (s, 1H), 12.20 (s, 1H), 7.60-
6.75 (m, 11H), 4.45 (d, 1H, J = 4 Hz), 3.45 (s, 3H), 3.40-3.25 (m, 
1H), 2.65-2.25 (m, 2H), 1.40-1.10 (m, 2H); FTIR 1632 cm 1 
(CO-HO); MS m/z 374 (0.2). Anal. (C24H22O4): C, H . 
l98-Dihydroxy-10-(2-phenylethylidene)-9(10H)-anthra-
cenone (7i). A suspension of 6i (0.5 g, 1.39 mmol) in absolute 
methanol (10 mL) was treated with DBU (1.1 g, 7.23 mmol). The 
reaction was terminated exactly after 3 min by the addition of 
excess 6 N HCl. The reaction mixture was shaken thoroughly 
and extracted with CH2CI2. The organic phase was dried over 
Na 2 S0 4 and then evaporated. The residue was purified by 
chromatography to afford 7i as yellow crystals (Table HI, 97% 
isomerically pure by HPLC analysis with respect to 8): *HNMR 
(250 MHz, CDCI3) ö 12.37 (s, 1H), 12.22 (s, 1H), 7.65-6.90 (m, 
11H), 6.68 (t, 1H, J = 7.4 Hz), 3.95 (d, 2H, J = 7.4 Hz); FTIR 
1630 cm 1 (CO-HO); MS m/z 328 (74). Anal. (C^H^Os): C , H . 
General Procedure for the Preparation of 1,8-Dihydroxy-
10-(u>-phenylalkylidene)-9( 10J7)-anthracenones 7a-h and 7j-
m. l^Dihyd>oxy-10-(3-phenylpn>pyUdene)-9(10J7)-anthra-
cenone (7j). A solution of 6j (0.5 g, 1.33 mmol) in pyridine (10 
mL) was refluxed under N 2 for 15-30 min until the reaction was 
completed (TLC control). The reaction mixture was then cooled 
and poured into water (200 mL), acidified with 6 N HCl, and 
extracted with CH 2C1 2 (3 x 20 mL). The combined C H ^ h 
extracts were washed with saturated aqueous NaCl, dried over 
Na 2S0 4 , and then evaporated. The residue was purified by 
chromatography to afford yellow crystals (Table III): l H NMR 
(CDCI3) 8 12.30 (s, 1H), 12.20 (s, 1H), 7.60-6.40 (m, 12H), 2.85 
(s, 4H); FTIR 1630 cm 1 (CO HO); MS m/z 342 (25). Anal 
(QaHuOa): C, H . 
10-[(4-Carboxyphenyl)methylene]-13-dihydroxy-9(10JI)-
anthracenone (7n). A suspension of 7e (0.5 g, 1.47 mmol) in 
50% sulfuric acid (40 mL) and glacial acetic acid (40 mL) was 
refluxed for 24 h. The reaction mixture was cooled in an ice 
bath, and the resulting crystals were filtered by suction and 
washed thoroughly with water, then with a small amount of cold 
Table IV. Chemical Data of 10-Phenylalkyl-Substituted l,8-Dihydroxy-9(10/f)-anthracenones 
OH O OH 
compd R 1 X R 2 formula0 mp (°C) yield {%) chromatography solvent (vol % Y anal.* 
6a H CH(OCH3) H C0H18O4 162-163 40 MC/H (9-11) C,H 
6b H CH(OCH3) 4-CH3 C23H20O4 137-138 33 MC/H (1-1) C,H 
6c H CH(OCH3) 4-CF3 C2 3HnF304 155-156 40 P/E (4-1) C,H 
6d H CH(OCH3) 4-N02 C^HnNOe 175-177 40 P/E (4-1) C, H , N 
6e H CH(OCH3) 4-CN C 2 3 H l 7 N0 4 165-166 40 MC/H (9-1) C, H , N 
6f H CH(OCH3) 4-OCH3 C23H2oOs 133-134 37 MC/H (4-1) C,H 
6g H CH(OCH3) 3,4-(OCH3)2 C24H2206 144-146 32 P/EA (13-7) C,H 
6h H CH(OCH3) 3,4,5-(OCH3)2 C s^H^O? 130-131 32 P/EA (13-7) C,H 
6i H CH(OCH3)CH2 H C23H2o04 140-141 20 MC C,H 
6j H CH(OCH3)(CH2)2 H C24H2204 138-139 18 MC C,H 
6k H CH(OCH3)(CH2)3 4-OCH3 C ^ ^ O s 83-85 42 MC C,H 
61 H CH(OCH3)(CH2)3 H 128-130 25 MC/H (7-3) C,H 
6m H CH(OCH3)(CH2)4 H C26H2604 68 17 MC/H (7-3) C,H 
8 H CH=CH H 186 64 MC C,H 
9a H CH 2 H C2iHi603 119* 20 P/EA (16-3) C,H 
9b H CH 2 4-N02 C 2 iH 1 5 N0 5 190-192 45 P/EA (6-3) C, H , N 
9c H CH 2 4-OCH3 135-136 20 MC/H (4-1) C,H 
10 CH2Ph CH 2 H C 2gH 2 20 3 205-206 22 MC/H (4-1) C,H 
°^ See footnotes of Table III. 
methanol, and then with petroleum ether (40-60) to afford a 
yellow powder (Table ni): X H NMR (DMSO-d6) h 12.10 (s, 1H), 
12.00 (s, 1H), 7.95-6.85 (m, 11H); FTIR1681 (COOH), 1630 cm 1 
(CO~HO); MS m/z 358 (82). Anal. (C^HuOs): C, H. 
l,8-Dihydroxy-10-[(4-(methoxycarbonyl)phenyl)-
methylene]-9(10H)-anthracenone (7o). A suspension of 7n 
(0.5 g, 1.40 mmol) in absolute methanol (160 mL) and 96 % 
sulfuric acid (0.5 mL) was refluxed for 24 h. The reaction mixture 
was cooled to -20 °C, and the resulting crystals were filtered by 
suction. Purification by chromatography gave orange-yellow 
crystals (Table HI): J H NMR (CDC13) 6 12.30 (s, 1H), 12.20 (s, 
1H), 8.10-6.90 (m, 11H), 3.95 (s, 3H); FTIR 1717 (C0 2CH 3), 1630 
cm-1 (CO-HO); MS m/z 372 (80). Anal. (C^eOs): C, H. 
General Procedure for the Cleavage of Methyl Ethers 
7p-r. l,8-Dihydroxy-10-[(4-hydroxyphenyl)methylene]-
9(1027)-anthracenone (7p). A solution of 7f (0.5 g, 1.45 mmol) 
in dry CH 2C1 2 (10 mL) was added dropwise to a solution of BBr 3 
(0.72 mL, 7.26 mmol) in CH 2C1 2 (20 mL) at-70 °C under N 2 . The 
mixture was allowed to warm to room temperature and stirred 
for 24 h. Excess water was added, and the mixture was extracted 
with ether. The ether phase was dried and evaporated and the 
residue purified by chromatography to afford 7p as orange-red 
crystals (Table IH): l H NMR (DMSO-d6) Ö 12.15 (s, 1H), 12.00 
(s, 1H), 9.80 (s, 1H), 7.70-6.60 (m, 11H); FTIR 3423 (OH), 1630 
cm-1 (CO HO); MS m/z 330 (100). Anal. (C^HwO*): C, H. 
(J5)-l,8-Dihydroxy-10-(2-phenylethenyl)-9(10H)-anthra-
cenone (8). A suspension of 6i (0.5 g, 1.39 mmol) in absolute 
methanol (10 mL) was treated with DBU (1.1 g, 7.23 mmol). The 
mixture was stirred at room temperature for 10 h, under N 2 and 
protected from light, until the reaction was completed by TLC 
analysis on silica gel RP-18, methanol/water/acetic acid (9-1-
0.1). The reaction mixture was shaken thoroughly with excess 
2 N HCl and extracted with CH2C12. The organic phase was 
dried over Na 2S0 4 and then evaporated. The residue was purified 
by chromatography to afford 8 as yellow crystals (Table IV, 64 %, 
>99% isomerically pure by HPLC analysis with respect to 7i): 
*H NMR (CDCU) 612.30 (s, 2H), 7.55-6.85 (m, 11H), 6.59 (d, 1H, 
J = 15 Hz), 6.06 (dd, 1H, J = 16/s Hz), 4.90 (d, 1H, J = 9 Hz); 
FTIR 1632 cm-1 (CO-HO); MS m/z 328 (99). Anal. (C^HieOa): 
C, H. 
General Procedure for the Preparation of 1,8-Dihydroxy-
10-(o>-phenylalkyl)-9(10H)-anthracenone8 9a-c. 1,8-Dihy-
droxy-10-(phenylmethyl)-9(10fl)-anthracenone (9a). An-
thralin (1,1 g, 4.42 mmol) and dry NajjCO:* (1.25 g) were suspended 
in absolute acetone (60 mL) under N 2 . Benzyl chloride (0.62 g, 
4.90 mmol) and catalytic amounts of potassium iodide were added, 
and the mixture was refluxed for 15 h under N 2 . Then the mixture 
was cooled, treated with water and 2 N sulfuric acid, and extracted 
exhaustively with CH 2C1 2. The combined organic extracts were 
washed with water, dried over Na 2S0 4, and then evaporated. 
The residue was purified by chromatography to afford 9a as yellow 
crystals (Table IV): lH NMR (CDCls) 5 11.95 (s, 2H), 7.50-6.30 
(m, 11H), 4.45 (t, 1H, J = 6 Hz), 3.05 (d, 2H, J = 6 Hz); FTIR 
1634 cm 1 (CO-HO); MS m/z 316 (24). Anal. (C2iH1603): C , H . 
13-Dihydroxy-10,10-bis(phenylmethyl)-9(10H)-anthra-
cenone (10). 10 was prepared from 1 (2 g, 8.84 mmol), benzyl 
chloride (2.8 g, 22.12 mmol), and dry Na 2 C0 3 (6 g) as described 
for 9a, but the reflux was maintained for 6 h. 10 was obtained 
as yellow crystals (Table IV): lH NMR (CDCla) 6 12.30 (s, 2H), 
7.75-6.30 (m, 16H), 3.65 (s, 4H); FTIR 1638 cm 1 (CO-HO); MS 
m/z 406 (22). Anal. (C^H^Os): C, H. 
log P Determination.45 The method is based on the linear 
relationship between the capacity factors log k' of the compounds 
and their log P values. The log k' values of five compounds 
(4-nitrophenol, 4-chlorophenol, benzophenone, naphthalene, and 
anthracene) with known log P values (1.91, 2.39,3.18,3.44, and 
4.49, respectively) were determined. A plot of log ^'versus log 
P generated from this calibration mixture was used for the 
calculation of log P values for unknowns from the logarithms of 
their chromatographic capacity factors (correlation coefficient 
> 0.99; n = 3). Methanol/ water/acetic acid (77-23-0.1), adjusted 
to pH 5.5 with concentrated N H 3 , was used as eluant. 
Determination of the Reducing Activitiy against 2,2-
Diphenyl-l-picrylhydrazyl . 1 9 To 1 mL of the test compound 
solution (10"4 M) was added 1 mL of DPPH solution (10*4 M), 
each in acetone/PBS (1-1 v/v), and the reduction of DPPH was 
followed spectrophotometrically at 516 nm. Plots of the reciprocal 
of DPPH concentrations against time gave straight lines, and 
the second-order rate constants were obtained from the slopes 
and are expressed as mean values (n = 3-6). 
Degradation of 2-Deoxy-D-ribose.19 The following reagents 
were added to glass tubes in the order and at the final 
concentrations stated: 0.3 mL of K H 2 P 0 4 - K O H buffer, pH 7.4 
(30 mM), 0.2 mL of H 2 0 (double distilled), 0.2 mL of 2-deoxy-
D-ribose (2 mM), 0.2 mL of FeCly6H 20 (0.1 mM), and 0.1 mL 
of anthracenone derivative (75 pM). Stock solutions of the 
compounds were made up fresh before use. Appropriate blanks 
and controls with the vehicle (acetonitrile) were conducted. The 
reaction mixtures were incubated for 2 h at 37 °C in a shaking 
water bath. Trichloroacetic acid (1.0 mL, 2.8% w/v) and 1.0 mL 
4106 Journal of Medicinal Chemistry, 1993, Vol. 36, No. 25 Müller et al. 
of 1% (w/v in 0.05 N NaOH) 2-thiobarbituric acid (TBA) were 
added, and the samples were heated at 100 °C for 15 min and 
then cooled in an ice bath (5 min). Then, 2.0 mL of the reaction 
mixtures was treated with 0.05 mL of 36% (w/v) HCl and 2.0 mL 
of 1-butanol, and the mixtures were vigorously shaken in a vortex 
mixer (Heidolph) for 15 s. The organic layer was separated by 
centrifugation at 1500g (15 min), and the absorbance at 532 run 
was measured against butanol. Calibration was performed using 
a malondialdehyde standard prepared by hydrolysis of 1,1,3,3,-
tetraethoxypropane.67 TBA-reactive material is expressed in 
terms of ^mol of MDA/mmol deoxyribose. 
Assay of Lipid Peroxidation in Bovine Brain Phospho-
lipid Liposomes. Bovine brain phospholipids were prepared 
essentially as described by Gutteridge.51 They were weighed into 
glass tubes and shaken in a vortex mixer (Heidolph) in the 
presence of five small glass beads (o.d. 4 mm) for 1 min. The 
phospholipids were suspended in 0.15 M NaCl, pH 7.4, to a final 
concentration of 5 mg/mL. The mixture was purged with N 2 for 
1 min and vigorously dispersed in a vortex mixer for 5 min. The 
liposomes were allowed to swell for 1 h at 4 °C. 
The following reagents were added to glass tubes in the order 
and at the final concentrations stated: 0.3 mL of KH2PO4-KOH 
buffer, pH 7.4 (30 mM), 0.19 mL of H 2 0 (double distilled), 0.2 
mL of liposomes (1 mg/mL), 0.2 mL of FeCl3-6H20 (0.1 mM), 0.1 
mL of ascorbic acid (0.1 mM), and 0.01 mL of anthracenone 
derivative (variable concentrations). Appropriate blanks and 
controls with the vehicles (acetone) were conducted. The reaction 
mixtures were incubated for 1 h at 37 °C in a shaking water bath. 
BHT (10 ML, 20% w/v), 0.5 mL of 25% (w/v) HCl, and 0.5 mL 
of 1% 2-thiobarbituric acid were added, and TBA-reactive 
material was measured as described above. 
Bovine P M N L 5-Lipoxygenase Assay. P M N L were pre-
pared essentially as described from sodium EDTA-anticoagulated 
bovine blood.37 Contaminating platelets were removed by 
repeated centrifugations at 100g for 20 min. The purified P M N L 
were suspended at a concentration of 1 x 107 cells/mL in 
phosphate-buffered saline (PBS, adjusted to pH 7.4 with 3 N 
N H 3 in a final volume of 1000 mL of double-distilled H 20). Cell 
counts were conducted with a Sysmex microcell counter CC-130. 
Preincubation was performed with 2.4 mL of the suspension and 
10 M L of a DMSO stock solution of the test compounds in PBS 
or vehicle control (DMSO at a final concentration of 0.4%) for 
15 min at 37 °C in a shaking water bath. CaCl 2 and Ca ionophore 
A23187 (final concentrations 2 mM and 20 pM, respectively) 
were added, and the incubation was conducted for 10 min at 37 
°C. 5-LO product formation was terminated by the addition of 
3.0 mL of methanol/acetonitrile (1-1) containing NDGA as a 
radical scavenger (final concentration 0.01 mM) and prostag-
landin B 2 as a chromatographic marker (final concentration 0.3 
pM). The incubation mixture was kept in an ice bath for 20 min 
and then centrifuged at 4000g for 5 min at 0 °C. The supernatant 
was diluted with 5 mL of water and passed through a prewashed 
(10 mL of methanol and 5 mL of water, sequentially) octade-
cylsilane reversed-phase cartridge (Baker). The eicosanoids were 
eluted with 3 mL of methanol, diluted with 3 mL of water and 
subjected to reversed-phase HPLC analysis. The isocratic elution 
conditions of L T B 4 were THF/methanol/water/acetic acid (25-
30-45-0.1), adjusted to pH 5.5 with concentrated N H 3 , flow rate 
0.9 mL/min, 280 run, whereas 5-HETE was monitored at 232 run 
using methanol/water/acetic acid (77-23-0.1), pH 5.5, flow rate 
1.0 mL/min. Data were recorded on a MacLab data acquisition 
system (WissTech, Germany), and analysis was performed with 
the software Peaks on an Apple Macintosh Quadra 700 computer. 
Integrated areas of the peaks were compared to the PGB 2 internal 
standard and to external standards of authentic samples. Molar 
absorption coefficients of Samuelsson et al. were used for the 
calculations.68 Inhibition was calculated by the comparison of 
the mean values of the test compound (n = 3) with the control 
(n = 6-8) activity: (1 - test compound/control) X100. Inhibition 
was statistically significant compared to that of the control 
(student's t test; p < 0.05). Each IC50 value was derived by 
interpolation of a log inhibitor concentration versus response 
plot using four or more concentrations of the compound, spanning 
the 50% inhibition point. Degradation of anthralin, 4p, and 7j 
under test conditions: The incubation mixture was diluted with 
10 mL of water and passed through an octadecylsilane reversed-
phase cartridge (Baker). After elution with 2 X 5 mL of water, 
the compounds were eluted with 3 X 1 mL of methanol and 
subjected to reversed-phase HPLC analysis. The isocratic elution 
conditions were methanol/water/acetic acid (85-15-0.1), 254 nm. 
The concentrations of the compounds and the metabolites 
bianthrone and danthron were determined from comparison of 
the corresponding peak area with known amounts of standards. 
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